US 12,252,537 B2
Antibody molecules that bind CD137 and OX40
Mihriban Tuna, Cambridge (GB); Miguel Gaspar, Cambridge (GB); Michelle Morrow, Cambridge (GB); and Edmund Poon, Cambridge (GB)
Assigned to INVOX PHARMA LIMITED, London (GB)
Appl. No. 17/259,796
Filed by F-star Beta Limited, Cambridge (GB)
PCT Filed Jul. 12, 2019, PCT No. PCT/EP2019/068796
§ 371(c)(1), (2) Date Jan. 12, 2021,
PCT Pub. No. WO2020/011966, PCT Pub. Date Jan. 16, 2020.
Claims priority of application No. 1811407 (GB), filed on Jul. 12, 2018; application No. 1818281 (GB), filed on Nov. 9, 2018; and application No. 1902598 (GB), filed on Feb. 26, 2019.
Prior Publication US 2022/0048996 A1, Feb. 17, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2818 (2013.01) [A61P 35/02 (2018.01); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/32 (2013.01); C07K 2317/565 (2013.01); C07K 2317/64 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
OG exemplary drawing
 
1. An antibody that binds to CD137 and OX40, comprising (a) a complementarity determining region (CDR)-based antigen-binding site for CD137 wherein the CDR-based antigen-binding site for CD137 comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3, defined according to the ImMunoGeneTics (IMGT) numbering scheme, comprising:
(i) SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively;
(ii) SEQ ID NOs: 1, 2, 16, 4, 5 and 6, respectively;
(iii) SEQ ID NOs: 1, 2, 21, 4, 5 and 6, respectively;
(iv) SEQ ID NOs: 25, 26, 27, 4, 5 and 28, respectively;
or (v) SEQ ID NOs: 33, 34, 35, 4, 5 and 36, respectively; and/or
wherein the CDR-based antigen-binding site for CD137 comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3, defined according to the Kabat numbering scheme, comprising:
(vi) SEQ ID NOs: 7, 8, 9, 10, 11 and 6, respectively;
(vii) SEQ ID NOs: 7, 8, 17, 10, 11 and 6, respectively;
(viii) SEQ ID NOs: 7, 8, 22, 10, 11 and 6, respectively;
(ix) SEQ ID NOs: 29, 30, 31, 10, 11 and 28, respectively; or
(x) SEQ ID NOs: 37, 38, 39, 10, 11 and 36, respectively; and
(b) an OX40 antigen-binding site located in a CH3 domain of the antibody, wherein the OX40 antigen-binding site comprises a first sequence comprising SEQ ID NO: 51 in the AB loop, a second sequence comprising SEQ ID NO: 52 in the CD loop, and a third sequence comprising SEQ ID NO: 53 in the EF loop of the CH3 domain according to the IMGT numbering scheme.